Drugs / ELE-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05434156 | Oct 2022 → Dec 2025 overdue | major depressive disorder | Eleusis Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELE-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05434156 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05434156 ↗ |